215 related articles for article (PubMed ID: 28819285)
1. Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
Gerboth S; Frittoli E; Palamidessi A; Baltanas FC; Salek M; Rappsilber J; Giuliani C; Troglio F; Rolland Y; Pruneri G; Kreutmair S; Pallavicini I; Zobel M; Cinquanta M; Minucci S; Gomez C; Santos E; Illert AL; Scita G
Leukemia; 2018 Mar; 32(3):820-827. PubMed ID: 28819285
[TBL] [Abstract][Full Text] [Related]
2. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.
Bassermann F; Jahn T; Miething C; Seipel P; Bai RY; Coutinho S; Tybulewicz VL; Peschel C; Duyster J
J Biol Chem; 2002 Apr; 277(14):12437-45. PubMed ID: 11790798
[TBL] [Abstract][Full Text] [Related]
3. Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation.
Sini P; Cannas A; Koleske AJ; Di Fiore PP; Scita G
Nat Cell Biol; 2004 Mar; 6(3):268-74. PubMed ID: 15039778
[TBL] [Abstract][Full Text] [Related]
4. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
[TBL] [Abstract][Full Text] [Related]
5. CIIA functions as a molecular switch for the Rac1-specific GEF activity of SOS1.
Hwang HS; Hwang SG; Cho JH; Chae JS; Yoon KW; Cho SG; Choi EJ
J Cell Biol; 2011 Oct; 195(3):377-86. PubMed ID: 22042618
[TBL] [Abstract][Full Text] [Related]
6. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.
Chang KH; Sanchez-Aguilera A; Shen S; Sengupta A; Madhu MN; Ficker AM; Dunn SK; Kuenzi AM; Arnett JL; Santho RA; Agirre X; Perentesis JP; Deininger MW; Zheng Y; Bustelo XR; Williams DA; Cancelas JA
Blood; 2012 Jul; 120(4):800-11. PubMed ID: 22692505
[TBL] [Abstract][Full Text] [Related]
7. Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia.
Gómez C; Garcia-Navas R; Baltanás FC; Fuentes-Mateos R; Fernández-Medarde A; Calzada N; Santos E
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010887
[TBL] [Abstract][Full Text] [Related]
8. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.
Skorski T; Wlodarski P; Daheron L; Salomoni P; Nieborowska-Skorska M; Majewski M; Wasik M; Calabretta B
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11858-62. PubMed ID: 9751755
[TBL] [Abstract][Full Text] [Related]
9. Sos1 Regulates Macrophage Podosome Assembly and Macrophage Invasive Capacity.
Baruzzi A; Remelli S; Lorenzetto E; Sega M; Chignola R; Berton G
J Immunol; 2015 Nov; 195(10):4900-12. PubMed ID: 26447228
[TBL] [Abstract][Full Text] [Related]
10. Induction of rac-guanine nucleotide exchange activity of Ras-GRF1/CDC25(Mm) following phosphorylation by the nonreceptor tyrosine kinase Src.
Kiyono M; Kaziro Y; Satoh T
J Biol Chem; 2000 Feb; 275(8):5441-6. PubMed ID: 10681520
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
Jain SK; Langdon WY; Varticovski L
Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
[TBL] [Abstract][Full Text] [Related]
12. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
[TBL] [Abstract][Full Text] [Related]
13. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.
Hodges TR; Abbott JR; Little AJ; Sarkar D; Salovich JM; Howes JE; Akan DT; Sai J; Arnold AL; Browning C; Burns MC; Sobolik T; Sun Q; Beesetty Y; Coker JA; Scharn D; Stadtmueller H; Rossanese OW; Phan J; Waterson AG; McConnell DB; Fesik SW
J Med Chem; 2018 Oct; 61(19):8875-8894. PubMed ID: 30205005
[TBL] [Abstract][Full Text] [Related]
15. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
Qiu X; Guo G; Chen K; Kashiwada M; Druker BJ; Rothman PB; Chen JL
Neoplasia; 2012 Jun; 14(6):547-58. PubMed ID: 22787435
[TBL] [Abstract][Full Text] [Related]
16. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs.
Daubon T; Chasseriau J; El Ali A; Rivet J; Kitzis A; Constantin B; Bourmeyster N
Oncogene; 2008 Apr; 27(19):2673-85. PubMed ID: 18059343
[TBL] [Abstract][Full Text] [Related]
17. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.
Thomas EK; Cancelas JA; Zheng Y; Williams DA
Leukemia; 2008 May; 22(5):898-904. PubMed ID: 18354486
[TBL] [Abstract][Full Text] [Related]
18. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Zhang X; Ren R
Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of guanine nucleotide exchange and Rac-mediated signaling revealed by a dominant negative trio mutant.
Debreceni B; Gao Y; Guo F; Zhu K; Jia B; Zheng Y
J Biol Chem; 2004 Jan; 279(5):3777-86. PubMed ID: 14597635
[TBL] [Abstract][Full Text] [Related]
20. Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.
Gao M; Huang ZL; Tao K; Xiao Q; Wang X; Cao WX; Xu M; Hu J; Feng WL
Oncotarget; 2017 Jan; 8(2):3304-3314. PubMed ID: 27926512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
